Alcon to Buy Neurotech for $550 Million, Gaining Cell Therapy ENCELTO
Start here
On October 20, 2026, Alcon announced an agreement to acquire Neurotech Pharmaceuticals for $550 million, with the core assets being the company's ophthalmic cell therapy platform and ENCELTO. ENCELTO, which received FDA approval in March 2025, treats macular telangiectasia type 2 in adults and is the first approved therapy for this indication in the United States. The deal may also include additional payments tied to commercialization milestones. The acquisition would strengthen Alcon's position in ophthalmic cell therapy, though the final terms, including any milestone payments, and the deal's closing have not been confirmed in the coverage.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatAlcon to Acquire Neurotech for $550 Million, Gaining Ophthalmic Cell Therapy ENCELTO
On October 20, 2026, Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million, with the core assets being the company's ophthalmic cell therapy platform and ENCELTO, which received FDA approval in March 2025. The deal may also include additional payments tied to commercialization milestones. ENCELTO treats macular telangiectasia type 2 in adults and is the first approved therapy for this indication in the United States.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 20:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.